Medicare Part B premiums to see big hike next year
CMS cited rising drug costs and the Covid-19 pandemic as the reason for the premium increases, which will rise to $170 in 2022 for people who make $91,000 or less.
Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drug
The U.S. district attorney for Massachusetts filed suit against the drugmaker this week, alleging that it paid tens of millions in kickbacks through a copay foundation for Eylea, a drug used to treat macular degeneration.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Critics blast Medicare drug pricing plan
The aim, the government says, is to maintain quality while slowing spending in Medicare Part B by more closely tying payments to how well drugs work, using methods drugmakers, insurers and benefit managers are already trying in the private sector.
Medicare ‘doc fix’ making things complicated with MIPS
Tom Lee, founder and CEO of SA Ignite, discusses why the new Medicare Merit-based Incentive Payment System, or MIPS, could be an administrative headache for medical practices and a boon for his company.
Report projects 50% increase in Medicare Part B premiums next year
The huge rate hike is predicted because of a confluence of two factors: Medicare Part B costs increased more than expected last year, and Social Security is not expected to have a cost of living increase next year.